ONCOCYTE CORPORATION

(OCX)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
1.110 USD   -0.89%
05/16Piper Sandler Trims OncoCyte's Price Target to $1.40 From $1.80, Maintains Overweight Rating
MT
05/12ONCOCYTE CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/12Needham Adjusts OncoCyte's Price Target to $2.25 From $4 on 'Peer Multiple Compression,' Reiterates Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Oncocyte Shares Drop 11% After Marketing Deal With Thermo Fisher

01/19/2022 | 10:13am EDT

By Chris Wack


Oncocyte Corp. shares fell 11% to $1.95 after the company said it was in a development and co-marketing agreement for two distributed in vitro diagnostic assays on Thermo Fisher Scientific's Ion Torrent Genexus System.

The company said the agreement grants Oncocyte rights to develop future companion diagnostics on the Genexus System.

Under the terms of the collaboration, Oncocyte will clinically validate Thermo Fisher's existing Oncomine Comprehensive Assay Plus on the Genexus System, working toward IVD clearance for use in tumor profiling and future submissions as a companion diagnostic.

Oncocyte shares ended Tuesday's session up 16%, and hit their 52-week low of $1.80 on Jan. 14.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

01-19-22 1013ET

Stocks mentioned in the article
ChangeLast1st jan.
ON SEMICONDUCTOR CORPORATION 0.70% 56.46 Delayed Quote.-16.87%
ONCOCYTE CORPORATION -0.89% 1.11 Delayed Quote.-48.85%
THERMO FISHER SCIENTIFIC 0.80% 555.15 Delayed Quote.-17.46%
All news about ONCOCYTE CORPORATION
05/16Piper Sandler Trims OncoCyte's Price Target to $1.40 From $1.80, Maintains Overweight R..
MT
05/12ONCOCYTE CORP Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/12Needham Adjusts OncoCyte's Price Target to $2.25 From $4 on 'Peer Multiple Compression,..
MT
05/11ONCOCYTE : Q1 Earnings Snapshot
AQ
05/11TRANSCRIPT : OncoCyte Corporation, Q1 2022 Earnings Call, May 11, 2022
CI
05/11ONCOCYTE CORP : Results of Operations and Financial Condition, Change in Directors or Prin..
AQ
05/11OncoCyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 202..
CI
05/11Oncocyte Reports First Quarter 2022 Financial Results
AQ
05/11Earnings Flash (OCX) ONCOCYTE CORPORATION Posts Q1 Revenue $1.4M
MT
05/05Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test
AQ
More news
Analyst Recommendations on ONCOCYTE CORPORATION
More recommendations
Financials (USD)
Sales 2022 9,48 M - -
Net income 2022 -50,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,27x
Yield 2022 -
Capitalization 136 M 136 M -
Capi. / Sales 2022 14,4x
Capi. / Sales 2023 6,36x
Nbr of Employees 113
Free-Float 91,9%
Chart ONCOCYTE CORPORATION
Duration : Period :
OncoCyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,11 $
Average target price 3,53 $
Spread / Average Target 218%
EPS Revisions
Managers and Directors
Ronald Asbury Andrews President, Chief Executive Officer & Director
Mitchell Stuart Levine Chief Financial Officer
Andrew Arno Chairman
Douglas T. Ross Chief Science Officer
Ekkehard Schütz Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCOCYTE CORPORATION-48.85%136
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612